HighProcurementSignal detected 20d ago
U.S. Section 232 Pharmaceutical Tariffs Implemented (July 31, 2026)
Liquid Dose Manufacturing Cmo →What Changed
The U.S. implemented Section 232 tariffs reaching up to 100% on imported patented pharmaceuticals and active ingredients on July 31, 2026. Importers can mitigate tariff rates to 20% or 0% by securing U.S. onshoring commitments with the Department of Commerce or agreeing to Most Favored Nation pricing. This policy enforcement forces liquid-dose CDMOs and sponsors to immediately realign offshore supply chains to minimize severe cost exposure.
At a Glance
Severity
High
Likelihood
High
Spend Exposed
-
Add your annual spend to quantify exposure:
$
Confidence
95%
Recommended Actions 1
Audit offshore liquid-dose CDMO footprint for Section 232 tariff exposure
Identifying affected imported ingredients and finished liquid doses enables procurement to negotiate tariff mitigation agreements or shift volume to domestic sites.